Page last updated: 2024-10-29

iodixanol and Syndrome

iodixanol has been researched along with Syndrome in 3 studies

iodixanol: dimeric contrast media; structure given in first source
iodixanol : A dimeric, non-ionic, water-soluble, radiographic contrast agent, used particularly in coronary angiography.

Syndrome: A characteristic symptom complex.

Research Excerpts

ExcerptRelevanceReference
"We performed a randomized, prospective, double blind trial comparing the use of the ionic dimer contrast agent ioxaglate 320 (Hexabrix) with the nonionic dimer contrast agent iodixanol 320 (Visipaque) in 618 patients undergoing percutaneous coronary intervention (PCI) for stable or unstable coronary artery syndromes."5.10A randomized prospective trial of ioxaglate 320 (Hexabrix) vs. iodixanol 320 (Visipaque) in patients undergoing percutaneous coronary intervention. ( Ashton, VJ; Campbell, PG; de Belder, MA; Hall, JA; Price, DJ; Sutton, AG, 2002)
" The secondary endpoints are absolute and relative increases in sCr of at least 50%, thrombolysis in myocardial infarction (TIMI) perfusion grade, and major adverse cardiac events at 1, 6, and 12 months."2.75The contrast media and nephrotoxicity following coronary revascularization by primary angioplasty for acute myocardial infarction study: design and rationale of the CONTRAST-AMI study. ( Angioli, P; Bolognese, L; Carrera, A; Ducci, K; Falsini, G; Grotti, S; Liistro, F; Limbruno, U; Picchi, A; Pierli, C, 2010)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lovy, AJ1
Rosenblum, JK1
Levsky, JM1
Godelman, A1
Zalta, B1
Jain, VR1
Haramati, LB1
Bolognese, L1
Falsini, G1
Grotti, S1
Limbruno, U1
Liistro, F1
Carrera, A1
Angioli, P1
Picchi, A1
Ducci, K1
Pierli, C1
Sutton, AG1
Ashton, VJ1
Campbell, PG1
Price, DJ1
Hall, JA1
de Belder, MA1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Contrast Media and Nephrotoxicity Following Coronary Revascularization by Primary Angioplasty for Acute Myocardial Infarction. The CONTRAST-AMI Study.[NCT00827788]Phase 4432 participants (Anticipated)Interventional2008-12-31Completed
Department of Geriatrics[NCT02575092]Phase 2/Phase 34,000 participants (Actual)Interventional2015-11-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

2 trials available for iodixanol and Syndrome

ArticleYear
The contrast media and nephrotoxicity following coronary revascularization by primary angioplasty for acute myocardial infarction study: design and rationale of the CONTRAST-AMI study.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2010, Volume: 11, Issue:3

    Topics: Acetylcysteine; Acute Kidney Injury; Angioplasty, Balloon, Coronary; Biomarkers; Contrast Media; Cor

2010
The contrast media and nephrotoxicity following coronary revascularization by primary angioplasty for acute myocardial infarction study: design and rationale of the CONTRAST-AMI study.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2010, Volume: 11, Issue:3

    Topics: Acetylcysteine; Acute Kidney Injury; Angioplasty, Balloon, Coronary; Biomarkers; Contrast Media; Cor

2010
The contrast media and nephrotoxicity following coronary revascularization by primary angioplasty for acute myocardial infarction study: design and rationale of the CONTRAST-AMI study.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2010, Volume: 11, Issue:3

    Topics: Acetylcysteine; Acute Kidney Injury; Angioplasty, Balloon, Coronary; Biomarkers; Contrast Media; Cor

2010
The contrast media and nephrotoxicity following coronary revascularization by primary angioplasty for acute myocardial infarction study: design and rationale of the CONTRAST-AMI study.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2010, Volume: 11, Issue:3

    Topics: Acetylcysteine; Acute Kidney Injury; Angioplasty, Balloon, Coronary; Biomarkers; Contrast Media; Cor

2010
A randomized prospective trial of ioxaglate 320 (Hexabrix) vs. iodixanol 320 (Visipaque) in patients undergoing percutaneous coronary intervention.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2002, Volume: 57, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Contrast Media; Double-Blind Method;

2002

Other Studies

1 other study available for iodixanol and Syndrome

ArticleYear
Acute aortic syndromes: a second look at dual-phase CT.
    AJR. American journal of roentgenology, 2013, Volume: 200, Issue:4

    Topics: Acute Disease; Aged; Aged, 80 and over; Aortic Diseases; Aortography; Case-Control Studies; Chi-Squa

2013